title: Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
abstract: Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients.
  
  
  BACKGROUND
  The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
  
  
  METHODS
  The effects of TPTD were examined between RA (n = 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (n = 62; age 71.3 years) with 77.4 % of prior BP.
  
  
  RESULTS
  Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %, P = 0.038), whereas it was 9.7 versus 7.9 % (P = 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (β = 0.446, P = 0.005) and baseline ucOC for FN (β = 0.554, P = 0.001), in which both showed significant negative correlation with baseline PSL dose.
  
  
  CONCLUSIONS
  RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.
authors.affiliation: Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan, k-ebina@umin.ac.jp.
authors.forename: K
authors.initials: K
authors.lastname: Ebina
authors.forename: J
authors.initials: J
authors.lastname: Hashimoto
authors.forename: K
authors.initials: K
authors.lastname: Shi
authors.forename: M
authors.initials: M
authors.lastname: Kashii
authors.forename: M
authors.initials: M
authors.lastname: Hirao
authors.forename: H
authors.initials: H
authors.lastname: Yoshikawa
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D006621:Hip Joint / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D019379:Teriparatide / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D019379:Teriparatide
references.citation: J Biol Chem. 2013 Oct 11;288(41):29809-20
references.pmid: 23963454
references.citation: Rheumatology (Oxford). 2005 Dec;44(12):1546-8
references.pmid: 16263785
references.citation: J Clin Invest. 2012 May;122(5):1791-802
references.pmid: 22505457
references.citation: Bone. 2010 Apr;46(4):935-9
references.pmid: 20060081
references.citation: Bone. 2011 Apr 1;48(4):798-803
references.pmid: 21168536
references.citation: J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80
references.pmid: 19584192
references.citation: Arthritis Rheum. 2006 Oct;54(10):3104-12
references.pmid: 17009229
references.citation: J Bone Miner Res. 2009 Jun;24(6):983-91
references.pmid: 19113922
references.citation: J Biol Chem. 2011 Dec 30;286(52):44326-35
references.pmid: 22030390
references.citation: Curr Osteoporos Rep. 2012 Jun;10(2):101-8
references.pmid: 22527726
references.citation: J Rheumatol. 2011 Aug;38(8):1680-8
references.pmid: 21572148
references.citation: Clin Exp Rheumatol. 2011 Nov-Dec;29(6):921-5
references.pmid: 22032557
references.citation: J Clin Endocrinol Metab. 2012 Feb;97(2):311-25
references.pmid: 22238383
references.citation: Rheumatology (Oxford). 2000 Dec;39(12):1383-9
references.pmid: 11136882
references.citation: J Bone Miner Res. 2005 Jun;20(6):962-70
references.pmid: 15883636
references.citation: Arthritis Rheum. 2009 Nov;60(11):3346-55
references.pmid: 19877063
references.citation: N Engl J Med. 2007 Aug 30;357(9):905-16
references.pmid: 17761594
references.citation: Nat Rev Endocrinol. 2013 Jan;9(1):43-55
references.pmid: 23147574
references.citation: Calcif Tissue Int. 2010 Dec;87(6):469-84
references.pmid: 20872215
references.citation: Endocrinology. 1995 Aug;136(8):3632-8
references.pmid: 7628403
references.citation: Ann Rheum Dis. 2007 Nov;66(11):1508-12
references.pmid: 17456523
references.citation: Ann Rheum Dis. 2009 Mar;68(3):330-6
references.pmid: 18375540
references.citation: J Bone Miner Res. 2004 Jun;19(6):893-9
references.pmid: 15125788
references.citation: J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62
references.pmid: 20631014
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Bone. 2013 Nov;57(1):272-6
references.pmid: 23981659
references.citation: Clin Exp Rheumatol. 2000 Nov-Dec;18(6):683-90
references.pmid: 11138329
references.citation: Arthritis Rheum. 2010 Jan;62(1):33-43
references.pmid: 20039425
references.citation: J Endocrinol Invest. 2012 Jul;35(7):661-4
references.pmid: 21970822
references.citation: J Clin Invest. 1999 Aug;104(4):439-46
references.pmid: 10449436
references.citation: J Clin Endocrinol Metab. 2008 Mar;93(3):852-60
references.pmid: 18160462
references.citation: Ann Rheum Dis. 1995 Oct;54(10):801-6
references.pmid: 7492217